Immune checkpoint inhibitors in ovarian cancer: where do we stand?

Alexandra Leary, David Tan, Jonathan Ledermann

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    43 Citations (Scopus)

    Résumé

    Numerous retrospective studies have demonstrated that the density of intra-tumoral immune cell infiltration is prognostic in epithelial ovarian cancer (OC). These observations together with reports of programmed death ligand-1 (PD-L1) expression in advanced OC provided the rationale for investigating the benefit of programmed death-1 (PD1) or PD-L1 inhibition in OC. Unfortunately clinical trials to date evaluating PD1/PD-L1 inhibition in patients with relapsed OC have been disappointing. In this review we will discuss early results from single agent PD1/PD-L1 inhibitors and the strategies to enhance benefit from immune-oncology agents in OC, including proposing anti-PD-L1 in combination with other agents (cytotoxics, anti-angiogenics, poly(ADP-ribose) polymerase. (PARP) inhibitors, targeted therapies or other immunotherapies), as well as evaluating these agents earlier in the disease course, or in biomarker selected patients.

    langue originaleAnglais
    journalTherapeutic Advances in Medical Oncology
    Volume13
    Les DOIs
    étatPublié - 1 janv. 2021

    Contient cette citation